Twist Bioscience (TWST) Change in Receivables (2017 - 2026)

Twist Bioscience has disclosed Change in Receivables across 10 years of filings, most recently posting $14.2 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 32.79% year-over-year to $14.2 million; the TTM figure through Mar 2026 stood at $14.5 million (up 2.24% YoY), while the FY2025 annual figure was $22.4 million, up 365.06% from the prior year.
• Change in Receivables improved to $14.2 million in Q1 2026, from -$6.8 million in the prior quarter.
• Over the last five years, Change in Receivables for TWST reached as high as $14.2 million in Q1 2026 and fell as low as -$8.1 million in Q4 2023.
• The 5-year median for Change in Receivables is $1.8 million (2022), against an average of $2.0 million.
• Annual changes were most pronounced in 2022 — Change in Receivables plunged 328.28% — and 2025, when it jumped 1531.96%.
• A 5-year view of Change in Receivables shows it stood at $4.1 million in 2022, then sank by 296.63% to -$8.1 million in 2023, then jumped by 156.3% to $4.5 million in 2024, then tumbled by 250.45% to -$6.8 million in 2025, then soared by 308.58% to $14.2 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $14.2 million, -$6.8 million, and $7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.